Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian C Shaffer

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
Blood Advances|June 8, 2022
Racial disparities in access to alternative donor allografts persist in the era of "donors for all"Warren B Fingrut, Boglarka Gyurkocza, Eric Davis, et al.
Blood Advances|April 26, 2024
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease preventionNoa G Holtzman, Lauren M Curtis, Rachel B Salit, et al.
Transplantation and Cellular Therapy|October 3, 2025
Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic TransplantationShannon R McCurdy, Scott R Solomon, Brian C Shaffer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 28, 2017
Impact of Toxicity on Survival for Older Adult Patients after CD34<sup>+</sup> Selected Allogeneic Hematopoietic Stem Cell TransplantationGunjan L Shah, Michael Scordo, Satyajit Kosuri, et al.
Blood Advances|October 6, 2025
Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamideDipenkumar Modi, Yosra M Aljawai, Todd E DeFor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated DonorsBrian C Shaffer, Mahasweta Gooptu, Todd E DeFor, et al.
American Journal of Hematology|September 9, 2023
Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemiaKarthik Nath, Jasme Lee, Theresa A Elko, et al.
Cancer Discovery|January 9, 2025
Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell TransplantsJinsuke Nishino, Wenhuo Hu, Ashwin Kishtagari, et al.
American Journal of Hematology|March 2, 2021
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapyBrian J Ball, Meier Hsu, Sean M Devlin, et al.
Blood Advances|May 27, 2025
Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantationIoannis Politikos, Samantha Brown, Joshua A Fein, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Blood Advances|June 8, 2022
Racial disparities in access to alternative donor allografts persist in the era of "donors for all"Warren B Fingrut, Boglarka Gyurkocza, Eric Davis, et al.
Blood Advances|April 26, 2024
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease preventionNoa G Holtzman, Lauren M Curtis, Rachel B Salit, et al.
Transplantation and Cellular Therapy|October 3, 2025
Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic TransplantationShannon R McCurdy, Scott R Solomon, Brian C Shaffer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 28, 2017
Impact of Toxicity on Survival for Older Adult Patients after CD34<sup>+</sup> Selected Allogeneic Hematopoietic Stem Cell TransplantationGunjan L Shah, Michael Scordo, Satyajit Kosuri, et al.
Blood Advances|October 6, 2025
Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamideDipenkumar Modi, Yosra M Aljawai, Todd E DeFor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated DonorsBrian C Shaffer, Mahasweta Gooptu, Todd E DeFor, et al.
American Journal of Hematology|September 9, 2023
Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemiaKarthik Nath, Jasme Lee, Theresa A Elko, et al.
Cancer Discovery|January 9, 2025
Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell TransplantsJinsuke Nishino, Wenhuo Hu, Ashwin Kishtagari, et al.
American Journal of Hematology|March 2, 2021
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapyBrian J Ball, Meier Hsu, Sean M Devlin, et al.
Blood Advances|May 27, 2025
Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantationIoannis Politikos, Samantha Brown, Joshua A Fein, et al.
Pageof 8